4552
JCR Pharmaceuticals Co.,Ltd.
ＪＣＲファーマ
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Notes
- Stock adjustmentsOct 1, 2020 Stock split 1 share → 4 shares
Key metrics
Revenue(million JPY)
Mar 2021
30,085
Mar 2022
51,082
Mar 2023
34,343
Mar 2024
42,871
Mar 2025
33,072
Operating profit(million JPY)
Mar 2021
8,269
Mar 2022
19,933
Mar 2023
4,975
Mar 2024
7,531
Mar 2025
-6,650
Operating profit margin(%)
Mar 2021
27.49
Mar 2022
39.02
Mar 2023
14.49
Mar 2024
17.57
Mar 2025
-20.11
Profit before tax(million JPY)
Mar 2021
8,653
Mar 2022
19,404
Mar 2023
5,412
Mar 2024
7,244
Mar 2025
-6,414
Profit(million JPY)
Mar 2021
6,892
Mar 2022
14,507
Mar 2023
3,772
Mar 2024
5,507
Mar 2025
-4,759
Total assets(million JPY)
Mar 2021
73,784
Mar 2022
97,134
Mar 2023
94,937
Mar 2024
102,226
Mar 2025
104,855
Cash and cash equivalents(million JPY)
Mar 2021
26,260
Mar 2022
30,733
Mar 2023
13,278
Mar 2024
18,756
Mar 2025
13,196
Cash flows from operating activities(million JPY)
Mar 2021
10,341
Mar 2022
9,289
Mar 2023
-5,500
Mar 2024
9,312
Mar 2025
-5,486
Cash flows from investing activities(million JPY)
Mar 2021
-3,290
Mar 2022
-3,250
Mar 2023
-15,002
Mar 2024
-2,690
Mar 2025
-9,874
Cash flows from financing activities(million JPY)
Mar 2021
8,304
Mar 2022
-2,179
Mar 2023
1,948
Mar 2024
-2,031
Mar 2025
9,736
Return on equity(%)
Mar 2021
19.8
Mar 2022
32.9
Mar 2023
7.4
Mar 2024
10.3
Mar 2025
-9.3
Equity ratio(%)
Mar 2021
51.3
Mar 2022
51.8
Mar 2023
54.2
Mar 2024
54.2
Mar 2025
44.8
Earnings per share(JPY per share)
Mar 2021
55.81
Mar 2022
117.26
Mar 2023
30.35
Mar 2024
44.13
Mar 2025
-38.43
Net assets per share(JPY per share)
Mar 2021
306.31
Mar 2022
406.57
Mar 2023
412.11
Mar 2024
443.62
Mar 2025
385.5
Dividend per share(JPY per share)
Mar 2021
12
Mar 2022
22
Mar 2023
20
Mar 2024
20
Mar 2025
20
Payout ratio(%)
Mar 2021
21.5
Mar 2022
18.76
Mar 2023
65.9
Mar 2024
45.32
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.